Medifast, Inc. (NYSE:MED) Q4 2024 Earnings Call Transcript
Operator: Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Medifast Inc (MED)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 903,734 | $15,923,793 | -11% | 0.02% |
| 2. | D E Shaw D. E. Shaw | 288,783 | $5,088,356 | +39% | 0% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 216,000 | $3,805,920 | +87% | 0% |
| 4. | GLG Partners Noam Gottesman | 195,556 | $3,445,697 | -6% | 0% |
| 5. | AQR Capital Management Cliff Asness | 174,384 | $3,072,646 | -55% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $68.89 | 50 | Director | 6,253 | 2023-11-07 | Filing | |
| $68.89 | 50 | Director | 8,375 | 2023-11-07 | Filing | |
| $68.89 | 53 | Director | 10,538 | 2023-11-07 | Filing | |
| $68.89 | 58 | Director | 5,784 | 2023-11-07 | Filing | |
| $70.55 | 97 | Director | 4,233 | 2023-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.46 | 2,753 | Director | 7,785 | 2024-03-08 | Filing | |
| $39.41 | 1,300 | Director | 10,538 | 2024-03-08 | Filing | |
| $73.87 | 5,613 | Other | 2,152 | 2023-10-06 | Filing | |
| $90.47 | 13,330 | Director | 1 | 2023-08-15 | Filing | |
| $89.79 | 9,832 | Director | 13,331 | 2023-08-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 919,364 | $16,199,194 | 0% | |
| 2. | 757,709 | $13,350,832 | 0% | |
| 3. | 353,005 | $6,219,948 | 0% | |
| 4. | 294,880 | $5,195,786 | 0.01% | |
| 5. | 286,006 | $5,039,442 | 0% |
News See All
Medifast, Inc. (NYSE:MED) Q3 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Medifast Third Quarter 2024 Earnings Conference Call. At this time, all participants are on a listen-only mode.
Medifast (MED): A Bull Case Theory
We came across a bullish thesis on Medifast (MED) on Value Degen’s Substack by Unemployed Value Degen. In this article we will summarize the bulls’ thesis on MED. Medifast, Inc.
Medifast, Inc. (NYSE:MED) Q2 2024 Earnings Call Transcript
Operator: And welcome to the Medifast Second Quarter 2024 Earnings Conference Call. At this time, all participants are on a listen-only mode.
Medifast, Inc. (NYSE:MED) Q1 2024 Earnings Call Transcript
Medifast, Inc. misses on earnings expectations. Reported EPS is $0.66 EPS, expectations were $0.78.
Here’s Why Miller Income Strategy Sold Medifast (MED)
Miller Value Partners, an investment management company, released its “Income Strategy” first-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Medifast, Inc. (NYSE:MED) Q4 2023 Earnings Call Transcript
Medifast, Inc. misses on earnings expectations. Reported EPS is $0.55 EPS, expectations were $0.99.
Reasons for the Decline of Medifast (MED) in Q4
Miller Value Partners, an investment management company, released its “Income Strategy” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here.
12 Very High Yield Dividend Stocks With Upside Potential
In this article, we discuss 12 very high yield dividend stocks with upside potential.
Billionaire Jim Simons’ Top 12 High-Dividend Stocks
In this article, we discuss billionaire Jim Simons' top 12 high-dividend stocks.
Billionaire Hedge Funds
